[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604947":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":11,"studyPopulation":11,"armGroups":48,"interventions":55,"overallOfficials":11,"centralContacts":61,"locations":71,"responsibleParty":190,"collaborators":11,"id":192,"slug":11,"hasResults":193,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":11,"eligibilityCriteria":197,"healthyVolunteers":193,"sex":198,"minAge":199,"maxAge":11,"enrollmentInfo":200,"targetDuration":11,"studyType":203,"phases":204,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},{"fullName":5,"class":6},"Immunocore Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":11},[9,13,15,17],{"measure":10,"description":11,"timeFrame":12},"Percentage of participants with dose-limiting toxicities (DLT)",null,"Up to ~16 months",{"measure":14,"description":11,"timeFrame":12},"Percentage of participants with adverse events (AE)",{"measure":16,"description":11,"timeFrame":12},"Percentage of participants with serious adverse events (SAE)",{"measure":18,"description":19,"timeFrame":12},"Percentage of participants with a dose interruption, reduction, or discontinuation","Percentage of participants with dosing changes or discontinuations.",[21,24,26,28,31,33,36,39],{"measure":22,"description":11,"timeFrame":23},"Best Overall Response (BOR) as determined by RECIST v1.1 per the Investigator.","Up to ~19 months",{"measure":25,"description":11,"timeFrame":23},"Duration of Response (DOR) as determined by RECIST v1.1 per the Investigator.",{"measure":27,"description":11,"timeFrame":23},"Progression Free Survival (PFS) as determined by RECIST v1.1 per the Investigator.",{"measure":29,"description":30,"timeFrame":23},"Overall Survival (OS)","OS is the time from first dose of study therapy until death due to any cause.",{"measure":32,"description":32,"timeFrame":23},"Change from baseline in lymphocyte counts",{"measure":34,"description":35,"timeFrame":23},"Changes in serum cytokine concentrations","Change from baseline in serum cytokine concentrations",{"measure":37,"description":38,"timeFrame":23},"IMC-P115C Plasma Concentration","IMC-P115C plasma concentration",{"measure":40,"description":11,"timeFrame":23},"Percentage of participants with anti-IMC-P115C antibody formation",{"allocation":42,"interventionModel":43,"interventionModelDescription":44,"primaryPurpose":45,"observationalModel":11,"timePerspective":11,"maskingInfo":46},"NA","SEQUENTIAL","The study will include sequential assignment for non-randomized and randomized arms.","TREATMENT",{"masking":47,"maskingDescription":11,"whoMasked":11},"NONE",[49],{"label":50,"type":51,"description":52,"interventionNames":53},"Arm A: IMC-P115C Monotherapy","EXPERIMENTAL","Participants receive IMC-P115C intravenous (IV) infusion",[54],"Drug: IMC-P115C",[56],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"DRUG","IMC-P115C","IV infusion",[50],[62,67],{"name":63,"role":64,"phone":65,"phoneExt":11,"email":66},"Immunocore Medical Information Global","CONTACT","844-466-8661","medical.information@immunocore.com",{"name":68,"role":64,"phone":69,"phoneExt":11,"email":70},"Immunocore Medical Information EU","+00 800-744-51111","medinfo.eu@immunocore.com",[72,85,94,103,114,123,132,143,149,158,169,175,184],{"facility":73,"status":74,"city":75,"state":11,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":11},"Cancer Research South Australia (CRSA)","RECRUITING","Adelaide","5000","Australia","AU",{"type":80,"coordinates":81},"Point",[82,83],138.59863,-34.92866,{"lat":83,"lon":82},{"facility":86,"status":74,"city":87,"state":11,"zip":88,"country":77,"countryCode":78,"cosmosGeoPoint":89,"geoPoint":93,"contacts":11},"Linear Clinical Research ltd.","Nedlands","06009",{"type":80,"coordinates":90},[91,92],115.8073,-31.98184,{"lat":92,"lon":91},{"facility":95,"status":74,"city":96,"state":11,"zip":97,"country":77,"countryCode":78,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"Melanoma Institute Australia","Wollstonecraft","2065",{"type":80,"coordinates":99},[100,101],151.18981,-33.8328,{"lat":101,"lon":100},{"facility":104,"status":74,"city":105,"state":11,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":11},"UNICANCER - Centre Leon-Berard (CLB)","Lyon","69008","France","FR",{"type":80,"coordinates":110},[111,112],4.84789,45.74906,{"lat":112,"lon":111},{"facility":115,"status":74,"city":116,"state":11,"zip":117,"country":107,"countryCode":108,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)","Toulouse","31059",{"type":80,"coordinates":119},[120,121],1.44367,43.60426,{"lat":121,"lon":120},{"facility":124,"status":74,"city":125,"state":11,"zip":126,"country":107,"countryCode":108,"cosmosGeoPoint":127,"geoPoint":131,"contacts":11},"Institut Gustave Roussy","Villejuif","94805",{"type":80,"coordinates":128},[129,130],2.35992,48.7939,{"lat":130,"lon":129},{"facility":133,"status":74,"city":134,"state":11,"zip":135,"country":136,"countryCode":137,"cosmosGeoPoint":138,"geoPoint":142,"contacts":11},"Fondazione IRCCS - Istituto Nazionale dei Tumori","Milan","20133","Italy","IT",{"type":80,"coordinates":139},[140,141],12.59836,42.78235,{"lat":141,"lon":140},{"facility":144,"status":74,"city":134,"state":11,"zip":145,"country":136,"countryCode":137,"cosmosGeoPoint":146,"geoPoint":148,"contacts":11},"Istituto Europeo di Oncologia","20141",{"type":80,"coordinates":147},[140,141],{"lat":141,"lon":140},{"facility":150,"status":74,"city":151,"state":11,"zip":152,"country":136,"countryCode":137,"cosmosGeoPoint":153,"geoPoint":157,"contacts":11},"Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\"","Naples","80131",{"type":80,"coordinates":154},[155,156],14.26811,40.85216,{"lat":156,"lon":155},{"facility":159,"status":74,"city":160,"state":11,"zip":161,"country":162,"countryCode":163,"cosmosGeoPoint":164,"geoPoint":168,"contacts":11},"Hospital Universitari Vall d Hebron","Barcelona","08035","Spain","ES",{"type":80,"coordinates":165},[166,167],2.15899,41.38879,{"lat":167,"lon":166},{"facility":170,"status":74,"city":160,"state":11,"zip":171,"country":162,"countryCode":163,"cosmosGeoPoint":172,"geoPoint":174,"contacts":11},"Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals","08908",{"type":80,"coordinates":173},[166,167],{"lat":167,"lon":166},{"facility":176,"status":74,"city":177,"state":11,"zip":178,"country":162,"countryCode":163,"cosmosGeoPoint":179,"geoPoint":183,"contacts":11},"Hospital Universitario Ramon y Cajal","Madrid","28034",{"type":80,"coordinates":180},[181,182],-3.70256,40.4165,{"lat":182,"lon":181},{"facility":185,"status":74,"city":177,"state":11,"zip":186,"country":162,"countryCode":163,"cosmosGeoPoint":187,"geoPoint":189,"contacts":11},"START Madrid - Hospital Universitario Fundación Jiménez Díaz","28040",{"type":80,"coordinates":188},[181,182],{"lat":182,"lon":181},{"type":191,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100604947",false,"NCT07156136","Study of IMC-P115C in Advanced PRAME-Positive Cancers","A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* HLA-A\\*02:01-positive\n* Meeting PRAME-positive tumor testing requirements\n* Metastatic or unresectable solid tumors\n* Have received (or be receiving), relapsed from, be refractory to or intolerant of all therapies\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* Symptomatic or untreated central nervous system metastasis\n* Bowel obstruction, perforation, or fistula formation within 3 months prior to the planned first dose of study treatment\n* Ongoing ascites or effusion requiring recent drainages\n* Significant ongoing toxicity from prior anticancer treatment\n* Out-of-range laboratory values\n* Clinically significant lung, heart, or autoimmune disease\n* Ongoing requirement for immunosuppressive treatment\n* Significant secondary malignancy\n* Hypersensitivity to study drug or excipients\n* Pregnant or lactating","ALL","18 Years",{"count":201,"type":202},140,"ESTIMATED","INTERVENTIONAL",[205],"PHASE1","Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.",[208,209,210],"PRAME Positive","Cancer","HLA-A*02:01-positive",[212],"PRAME","2026-02-23",{"date":215,"type":216},"2026-02-25","ACTUAL",{"date":218,"type":216},"2024-11-07",{"date":220,"type":202},"2029-08-30",{"name":5,"class":6},13]